Pulmonaryhypertension in Copd at Different Levels of Smoking

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

138 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To identify Predictors of pulmonary hypertension in COPD patients and its relation to different levels of smoking

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of Pulmonary Hypertension in COPD Patients

NCT00614900

COPD Pulmonary Hypertension

COMPLETED

Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy

NCT06613321

Copd Hypertension, Pulmonary Hyperdistention

COMPLETED

Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China

NCT03185572

COPD Pulmonary Hypertension

UNKNOWN

Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD

NCT03110614

Chronic Obstructive Pulmonary Disease Diastolic Dysfunction

COMPLETED

Blood Hpercoagublity in Copd

NCT05380960

Blood Coagulability in Copd

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.It is also the most common cause of deaths in patients with chronic respiratory disease, the fatality rate in USA is 0.41%.Pulmonary Hypertension is the most common serious complication in COPD patients ; which occurs in up to 30% of patients and increases the mortality rate.Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) Smoking is also a trigger for COPD flare-ups.Smoking damages the air sacs, airways, and the lining of your lungs. Injured lungs have trouble moving enough air in and out, so it's hard to breathe

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Echocardiography and HRCT

Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.All patients admitted to chest department or presented to our outpatient clinic with clinical and functional diagnosis of COPD among both sexes will be included 2.Age \>18 years Old

Exclusion Criteria

* 1.Patients under 18 years old. 2.pregnant patients. 3.patients with history hypertension or valvular diseases 4.Cardiomyopathic patient 5.Patients with concomitant obstructive sleep apnea 6.Patients with collagen vascular disease 7.Patients with thrombo-embolic disease 8. Patients with any chronic chest disease other than COPD

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No